Skip to main content
SpringerLink
Log in

Advances in the Pharmacological Treatment of Gastro-Oesophageal Cancer

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Despite a sharp decline in the incidence of gastric cancer during the second half of the 20th century, this malignancy remains the second leading cause of cancer mortality in the world. The incidence and mortality rate of gastric cancer increase with age; at present, the median ages at diagnosis are 67 years for men and 72 years for women in the US. This article reviews and discusses current medical treatment options for both the general population and elderly gastric cancer patients.

Management of localized gastric cancer has changed significantly over recent years. Adjuvant chemoradiation is not generally recommended outside the US. After decades of trials of adjuvant chemotherapy with inconclusive results, a significant survival benefit for perioperative combination chemotherapy — as compared with surgery alone — in patients with resectable or locally advanced gastro-oesophageal cancer was recently demonstrated in the UK MAGIC trial. A further large, randomized trial from Japan demonstrated a significant survival benefit for adjuvant chemotherapy with S-1 after D2 resection for gastric cancer. However, both trials are applicable only to the population in which the trials were conducted. Specific data on elderly patients are missing.

For patients with metastatic disease, oral fluoropyrimidines, such as capecitabine, have been developed. In Asian patients, treatment with the oral fluoropyrimidine S-1 is safe and effective. Docetaxel, oxaliplatin and irinotecan have demonstrated activity against gastric cancer in appropriately designed, randomized, phase III trials and have increased the available treatment options significantly. In addition, according to preliminary data, trastuzumab in combination with chemotherapy has significantly improved activity when compared to chemotherapy alone in patients with human epidermal receptor (HER)-2-positive gastric and gastro-oesophageal cancers. Thus, therapeutic decisions in patients with advanced gastric cancer may be adapted to the molecular subtype and co-morbidities of the individual patient. Data from retrospective analyses suggest that oxaliplatin seems to be better tolerated than cisplatin in elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003; 56(1): 1–9

    Article  PubMed  Google Scholar 

  2. Ferlay J, Bray J, Pisani P, et al. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. Version 1.0 ed. Lyon: IARC Press, 2001

    Google Scholar 

  3. Zitierweise. Krebs in Deutschland 2003–2004. Häufigkeiten und Trends. 6. überarbeitete Auflage. Berlin: Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen, Krebsregister in Deutschland e. V. (Hrsg), 2008

  4. Ries LAG, Melbert D, Krapcho M, et al., editors. SEER Cancer statistics review, 1975–2005 [based on November 2007 SEER data submission, posted to the SEER web site]. Bethesda (MD): National Cancer Institute, 2008 [online]. Available from URL: http://seer.cancer.gov/csr/1975_2005 [Accessed 2009 Jun 9]

    Google Scholar 

  5. Yancik R, Ries LA. Aging and cancer in America: demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000; 14(1): 17–23

    Article  PubMed  CAS  Google Scholar 

  6. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on US cancer burden. Cancer 2002; 94(10): 2766–92

    Article  PubMed  Google Scholar 

  7. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21(7): 1383–9

    Article  PubMed  Google Scholar 

  8. Saito H, Osaki T, Murakami D, et al. Effect of age on prognosis in patients with gastric cancer. ANZ J Surg 2006; 76(6): 458–61

    Article  PubMed  Google Scholar 

  9. Buffart TE, Carvalho B, Hopmans E, et al. Gastric cancers in young and elderly patients show different genomic profiles. J Pathol 2007; 211(1): 45–51

    Article  PubMed  CAS  Google Scholar 

  10. Ubenstein LZ, Josephson KR, Wieland GD, et al. Effectiveness of a geriatric evaluation unit: a randomized clinical trial. N Engl J Med 1984; 311(26): 1664–70

    Article  Google Scholar 

  11. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16(4): 1582–7

    PubMed  CAS  Google Scholar 

  12. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20(2): 494–502

    Article  PubMed  Google Scholar 

  13. Wedding U, Ködding D, Pientka L, et al. Physicians judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit Rev Oncol Hematol 2007; 64: 1–9

    Article  PubMed  Google Scholar 

  14. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the Task Force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55(3): 241–52

    Article  PubMed  Google Scholar 

  15. Overcash JA, Beckstead J, Extermann M, et al. The abbreviated comprehensive geriatric assessment (aCGA): a retrospective analysis. Crit Rev Oncol Hematol 2005; 54(2): 129–36

    Article  PubMed  Google Scholar 

  16. Roehrig B, Hoeffken K, Pientka L, et al. How many and which items of activities of daily living (ADL) and instrumental activities of daily living (IADL) are necessary for screening? Crit Rev Oncol Hematol 2007; 62(2): 164–71

    Article  PubMed  Google Scholar 

  17. Winograd CH, Gerety B, Chung M, et al. Screening for frailty: criteria and predictors of outcomes. J Am Geriatr Soc 1991; 39(8): 778–84

    PubMed  CAS  Google Scholar 

  18. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base report on poor survival of US gastric carcinoma patients treated with gastrectomy. 5th ed. In: American Joint Committee on Cancer staging, proximal disease, and the ‘different disease’ hypothesis. Cancer 2000; 88 (4): 921–32

    Google Scholar 

  19. Siewert JR, Bottcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228(4): 449–61

    Article  PubMed  CAS  Google Scholar 

  20. Cunningham D, Oliveira J. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19Suppl. 2: ii23–4

    Article  PubMed  Google Scholar 

  21. Gastric cancer treatment. Bethesda (MD): National Cancer Institute, 2008 May 16 [online]. Available from URL:http://www.cancer.gov/cancertopics/pdq/treatment/gastric/HealthProfessional/page8 [Accessed 2008 Oct 15]

  22. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355(1): 11–20

    Article  PubMed  CAS  Google Scholar 

  23. Macadam R, Sarela A, Wilson J, et al. Bone marrow micrometastases predict early post-operative recurrence following surgical resection of oesophageal and gastric carcinoma. Eur J Surg Oncol 2003; 29(5): 450–4

    Article  PubMed  Google Scholar 

  24. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345(10): 725–30

    Article  PubMed  CAS  Google Scholar 

  25. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35(7): 1059–64

    Article  PubMed  CAS  Google Scholar 

  26. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002; 168(11): 597–608

    Article  PubMed  CAS  Google Scholar 

  27. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials: a study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 2000; 11(7): 837–43

    Article  PubMed  CAS  Google Scholar 

  28. Nakajima T, Kinoshita T, Nashimoto A, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007; 94(12): 1468–76

    Article  PubMed  CAS  Google Scholar 

  29. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357(18): 1810–20

    Article  PubMed  CAS  Google Scholar 

  30. Ajani JA, Faust J, Ikeda K, et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005; 23(28): 6957–65

    Article  PubMed  CAS  Google Scholar 

  31. Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC AC-CORD07-FFCD 9703 [abstract]. J Clin Oncol 2007; 25(18S): 4510

    Google Scholar 

  32. Wagner AD, Grothe W, Behl S, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2005; (2): CD004064

  33. Ilson DH. Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol 2007; 25(22): 3188–90

    Article  PubMed  CAS  Google Scholar 

  34. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15(1): 110–5

    PubMed  CAS  Google Scholar 

  35. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34(8): 1274–81

    Article  PubMed  CAS  Google Scholar 

  36. McGavin JK, Goa KL. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Drugs 2001; 61(15): 2309–26

    Article  PubMed  CAS  Google Scholar 

  37. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001; 40(2): 85–104

    Article  PubMed  CAS  Google Scholar 

  38. European Medicines Agency. Capecitabine SMPC: scientific discussion [online]. Available from URL: http://www.emea.europa.eu [Accessed 2008 Oct 01]

  39. Cassidy J, Twelves C, Cameron D, et al. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 1999; 44(6): 453–60

    Article  PubMed  CAS  Google Scholar 

  40. Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999; 5(7): 1696–702

    PubMed  CAS  Google Scholar 

  41. Kang Y, Kang WK, Shin DB, et al. Randomized phase III trial of capecitabine/cisplatin (XP) versus continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results [abstract]. J Clin Oncol 2006; 24(18S): LBA4018

    Google Scholar 

  42. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358(1): 36–46

    Article  PubMed  CAS  Google Scholar 

  43. Okines AF, Norman AR, McCloud PI, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. Epub 2009 May 27

    Google Scholar 

  44. Kubota T. The role of S-1 in the treatment of gastric cancer. Br J Cancer 2008; 98(8): 1301–4

    Article  PubMed  CAS  Google Scholar 

  45. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9(3): 215–21

    Article  PubMed  CAS  Google Scholar 

  46. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21(1): 54–9

    Article  PubMed  CAS  Google Scholar 

  47. Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS). 6th ASCO GI Cancer Symposium; 2009 Jan 15–17; San Francisco (CA). Chestnut Hill (MA): American Society of Clinical Oncology, 2009

    Google Scholar 

  48. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26(9): 1435–42

    Article  PubMed  CAS  Google Scholar 

  49. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study — FFCD 9803. J Clin Oncol 2004; 22(21): 4319–28

    Article  PubMed  CAS  Google Scholar 

  50. Moehler M, Eimermacher A, Siebler J, et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92(12): 2122–8

    Article  PubMed  CAS  Google Scholar 

  51. Pozzo C, Barone C, Szanto J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004; 15(12): 1773–81

    Article  PubMed  CAS  Google Scholar 

  52. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19(8): 1450–7

    Article  PubMed  CAS  Google Scholar 

  53. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24(31): 4991–7

    Article  PubMed  Google Scholar 

  54. Tebbutt NC, Norman A, Cunningham D, et al. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophagogastric cancer. Ann Oncol 2002; 13(10): 1568–75

    Article  PubMed  CAS  Google Scholar 

  55. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18(14): 2648–57

    PubMed  CAS  Google Scholar 

  56. Field K, Michael M, Leong T. Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 2008; 68(3): 299–317

    Article  PubMed  CAS  Google Scholar 

  57. Kollmannsberger C, Quietzsch D, Haag C, et al. A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000; 83(4): 458–62

    Article  PubMed  CAS  Google Scholar 

  58. Murad AM, Petroianu A, Guimaraes RC, et al. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol 1999; 22(6): 580–6

    Article  PubMed  CAS  Google Scholar 

  59. Thuss-Patience PC, Kretzschmar A, Repp M, et al. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 2005; 23(3): 494–501

    Article  PubMed  CAS  Google Scholar 

  60. Ridwelski K, Fahlke J, Kettner E, et al. Docetaxel-cisplatin (DC) vs 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: preliminary results of a phase III study [abstract]. J Clin Oncol 2008; 26(18S): 4512

    Google Scholar 

  61. Wagner AD, Wedding U, Kuss O, et al. Docetaxel for advanced gastric cancer? J Clin Oncol 2007; 25(17): 2490–1; author reply 2491–3

    Article  PubMed  Google Scholar 

  62. Wedding U, Honecker F, Bokemeyer C, et al. Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 2007; 14(1): 44–56

    PubMed  Google Scholar 

  63. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345(15): 1091–7

    Article  PubMed  CAS  Google Scholar 

  64. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004; 15(9): 1330–8

    Article  PubMed  CAS  Google Scholar 

  65. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24(25): 4085–91

    Article  PubMed  CAS  Google Scholar 

  66. Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008; 26(9): 1443–51

    Article  PubMed  CAS  Google Scholar 

  67. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285(21): 2750–6

    Article  PubMed  CAS  Google Scholar 

  68. Carey EC, Walter LC, Lindquist K, et al. Development and validation of a functional morbidity index to predict mortality in community-dwelling elders. J Gen Intern Med 2004; 19(10): 1027–33

    Article  PubMed  Google Scholar 

  69. Lee SJ, Lindquist K, Segal MR, et al. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006; 295(7): 801–8

    Article  PubMed  CAS  Google Scholar 

  70. Trumper M, Ross PJ, Cunningham D, et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer 2006; 42(7): 827–34

    Article  PubMed  CAS  Google Scholar 

  71. Graziano F, Santini D, Testa E, et al. A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. Br J Cancer 2003; 89(8): 1428–32

    Article  PubMed  CAS  Google Scholar 

  72. Santini D, Graziano F, Catalano V, et al. Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. BMC Cancer 2006; 6: 125

    Article  PubMed  CAS  Google Scholar 

  73. Nardi M, Azzarello D, Maisano R, et al. FOLFOX-4 regimen as fist-line chemotherapy in elderly patients with advanced gastric cancer: a safety study. J Chemother 2007; 19(1): 85–9

    PubMed  CAS  Google Scholar 

  74. Abbrederis K, Azzarello D, Maisano R, et al. Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer: results of a phase II study in elderly patients or patients with impaired performance status. Crit Rev Oncol Hematol 2008; 66(1): 84–90

    Article  PubMed  CAS  Google Scholar 

  75. Liu ZF, Guo QS, Zhang XQ, et al. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Am J Clin Oncol 2008; 31(3): 259–63

    Article  PubMed  Google Scholar 

  76. Lee JL, Kang YK, Kang HJ, et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 2008; 99(4): 584–90

    Article  PubMed  CAS  Google Scholar 

  77. Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002; 236(1): 37–42

    Article  PubMed  Google Scholar 

  78. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24(33): 5201–6

    Article  PubMed  CAS  Google Scholar 

  79. Takehana T, Kunitomo K, Suzuki S, et al. Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol 2003; 1(6): 438–45

    Article  PubMed  CAS  Google Scholar 

  80. Tokunaga A, Onda M, Okuda T, et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995; 75(6 Suppl.): 1418–25

    Article  PubMed  CAS  Google Scholar 

  81. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24(30): 4922–7

    Article  PubMed  CAS  Google Scholar 

  82. Doi T, Koizumi W, Siena S, et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer [abstract]. Proc Am Soc Clin Oncol 2003; 22: 1036

    Google Scholar 

  83. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007; 18(3): 510–7

    Article  PubMed  CAS  Google Scholar 

  84. Moehler M, Trarbach T, Seuferlein T, et al. Cetuximab with irinotecan/Na-Fa/5-FU as first-line treatment in advanced gastric cancer: preliminary results of a non-randomised multi-centre AIO phase II study. Proceedings of the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers. J Clin Oncol 2008; 26(18S): 112

    Google Scholar 

  85. Lordick F, Lorenzen S, Hegewisch-Becker S, et al. Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group [abstract]. J Clin Oncol 2007; 25(18S): 4526

    Google Scholar 

  86. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16(2): 273–8

    Article  PubMed  CAS  Google Scholar 

  87. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) [abstract no. LBA4509]. J Clin Oncol 2009; 27 Suppl.: 18s

    Article  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Ulrich Wedding has received lecture fees from Roche, Amgen, Ortho-Biotec, Novartis and GlaxoSmithKline, has acted as a consultant to Ortho-Biotec and has received study support from Ortho-Biotec. Anna Wagner has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Multidisciplinary Oncology Center, University of Lausanne Hospitals, Lausanne, Switzerland

    Anna Dorothea Wagner

  2. Department of Internal Medicine II, University Hospital Jena, Jena, Germany

    Ulrich Wedding

Authors
  1. Anna Dorothea Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Wedding
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna Dorothea Wagner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wagner, A.D., Wedding, U. Advances in the Pharmacological Treatment of Gastro-Oesophageal Cancer. Drugs Aging 26, 627–646 (2009). https://doi.org/10.2165/11315740-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11315740-000000000-00000

Keywords

Search

Navigation